Volterra Risk/Reward Deemed Favorable and 4 Stock Analyses to Follow

Amgen Inc. (NASDAQ:AMGN): Current Price: $82.11

According to Deutsche Bank, Amgen will update its 2015 guidance at its business review meeting, which is scheduled for February 7. Deutsche believes that the company’s current 2015 earnings outlook of $7.25 to $8.60 may be increased to $7.93 to $9.25 as a result of more aggressive share buybacks. The firm notes that the current consensus remains at the low end of its new projected guidance range. The firm reiterates its Buy rating and a $108 price target on the stock.

Capture

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

Viacom, Inc. (NASDAQ:VIAB): Current Price: $58.31

Goldman has decided to upgraded the U.S. Media sector considering the rise in demand for professional content, which improves 2H 2013 ad growth, along with above average capital returns. Additionally, the firm upgraded Viacom to Buy from Neutral.

Capture

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Volterra Semiconductor Corporation (NASDAQ:VLTR): Current Price: $16.99

Piper Jaffray believes that Volterra’s risk/reward is favorable into its Q4 earnings tonight. Piper predicts that the company’s results will be at the high-end of guidance, and it is convinced that an in-line quarter has the potential to lift the stock. The firm thinks that the results will be a positive catalyst, and it maintains its Overweight rating and a $22.50 price target on the stock.

Capture

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

Impax Laboratories Inc. (NASDAQ:IPXL): Current Price: $19.10

According to Leerink, Impax’s second Complete Response Letter, or CRL, from the FDA for Rytary will delay the drug’s launch to early 2014, versus Q1 of 2013. As a result, the firm reduced its price target for the company’s shares to $22 from $24, but it continues to expect approval. Leerink reiterates its Outperform rating on the stock.

Capture

Celldex Therapeutics, Inc. (NASDAQ:CLDX): Current Price: $7.61

Celldex has been added to Roth Capita’s Focus List due to potential opportunities and promising data for CDX-011 and rindopeplmut, along with a strong early stage pipeline. The firm gives the shares a $16 price target.

Capture

Investing Insights: A Quick Analysis of This Tech Stock.